1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

Mandate Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

August 13, 2020

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with its acquisition of a controlling interest of 62.7% of the French company Genkyotex SA, a leader in NOX inhibition therapies and listed on Euronext Paris and Euronext Brussels.

Calliditas is seeking to acquire all outstanding Genkyotex shares and will following completion of the control transaction, which is expected to close in October 2020, launch a mandatory cash tender offer on the same terms for the remaining shares.

Vinge’s team comprises Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Julia Hirschberg.





Summary of employment related news in Sweden as of January 2021

 Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not so long ago, sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and particularly the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Set forth below is a summary of some recent developments.
December 22, 2020